NeuroVive Pharmaceutical AB

NeuroVive is involved in research and development into drugs which protect nerve cells. The company is on the verge of conducting clinical trials in humans with the product NeuroSTAT®, but its business also includes advanced research and development of other variants of cyclophilin-D-inhibiting cyclosporines and studying new ways of transporting these drugs across the blood-brain barrier to the central nervous system.

NeuroVive intends to license products to major pharmaceutical companies for registration and marketing. The company will derive its income partly from fixed payments and partly from ongoing royalty income from sales of licensed products.